MindMaze Therapeutics Holding (RLFTF)

[nelskof]

It's a synthetic vasoactive intestinal peptide study that didn't show any significance. That raises my eyebrows.

The FDA told them they would have to complete a larger trial in addition to the 2 different 70 patient studies. And we are trying to do it with 102, or potentially 144. That definitely makes me have cause for concern.

“While extremely difficult to make, our decision to discontinue the VANGARD trial came after a review of the rapidly evolving COVID-19 treatment landscape, the changing regulatory path, the results of the interim data analysis and the potential benefit to patients of advancing this program versus deploying our resources to other studies,” said Jonathan Mow, Chief Executive Officer, PhaseBio Pharmaceuticals.